All In Biotech

Drug Trial Radar · NCT02370537

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI

Last checked: Nov 20, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

490

Actual

Start

Mar 2015

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to investigate the pharmacokinetics (PK) of EPANOVA® (omega-3 carboxylic acids) and omega-3-acid ethyl esters (OMACOR®, Abbott Healthcare Products Ltd) following a single oral dose in patients with different degrees of PEI.

Conditions

  • Diabetes Mellitus, Type 2
  • Exocrine Pancreatic Insufficiency

Interventions

  • Epanova® (omega-3 carboxylic acids)Drug

    4 g (administered orally as 4 x 1 g capsules)

  • Omacor® (omega-3-acid ethyl esters)Drug

    4 g (administered orally as 4 x 1 g capsules)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Serum TG Level.Time frame: 7 days after enrollment.
  2. Part B: Baseline Corrected Area Under the Plasma Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) for Total Eicosapentaenoic Acid (EPA) Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
  3. Part B: Baseline Corrected AUC(0-last) for Total Docosahexaenoic Acid (DHA) Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
  4. Part B: Baseline Corrected AUC(0-last) for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
  5. Part B: Baseline Corrected Maximum Plasma Drug Concentration (Cmax) for Total EPA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
  6. Part B: Baseline Corrected Cmax for Total DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.
  7. Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.Time frame: Blood samples for analysis were taken at 1, 0.5, and 0.05 hours pre-dose, to be used as baseline, and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 hours post-dose.

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Aarhus, Denmark

  • Research Site

    Frederiksberg, Denmark

  • Research Site

    København NV, Denmark

  • Research Site

    Balatonfüred, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Létavértes, Hungary

  • Research Site

    Daugavpils, Latvia

  • Research Site

    Jēkabpils, Latvia

  • Research Site

    Riga, Latvia

  • Research Site

    Bialystok, Poland

  • Research Site

    Puławy, Poland

  • Research Site

    Staszów, Poland

  • Research Site

    Zamość, Poland

  • Research Site

    Bardejov, Slovakia

  • Research Site

    Bratislava, Slovakia

  • Research Site

    Ľubochňa, Slovakia

  • Research Site

    Gothenburg, Sweden

  • Research Site

    Linköping, Sweden

  • Research Site

    Lund, Sweden

  • Research Site

    Malmö, Sweden

  • Research Site

    Stockholm, Sweden

  • Research Site

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.